GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
News
NHS England pledges £10m to support GP services over winter
NHS England says it will provide £10 million to GPs to help support delivery of additional extended hours, out of hours and unscheduled care sessions over the winter period.
US green light for Pfizer’s lung cancer drug
Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.
Lilly’s snaps up Chugai’s experimental diabetes drug
Lilly has entered into an agreement to develop Chugai’s OWL833, a oral non-peptidic GLP-1 receptor agonist currently in Phase I for type II diabetes.
Janssen hands back rights to imetelstat
Janssen Biotech has decided to terminate a collaboration and license agreement with Geron Corp for experimental cancer drug imetelstat.
FDA accepts Allergan’s Vraylar for review
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Draft NICE decision rejects Respreeza for incurable, genetic disorder
NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency.
Roche to file entrectinib for ROS-1 positive NSCLC
Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients with ROS1-positive non-small cell lung cancer (NSCLC).
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.
Life expectancy growth stalls for the first time since 1982
Life expectancy in the UK has stopped increasing for the first time since 1982, show new data released by the Office for National Statistics.
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Novartis to shutter Grimsby site amid manufacturing overhaul
Novartis has announced plans to close its manufacturing site in Grimsby, UK, by the end of 2020, among a wider job cull likely to affect more than 2,200 positions in the country and Switzerland.
US clears Verastem’s Copiktra for blood cancers
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma after at least two prior therapies.
Farxiga cuts hospitalisation for heart failure or CV death, study shows
AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
EC clears AZ’ Imfinzi for locally-advanced, unresectable NSCLC
AstraZeneca’s Imfinzi has been approved in Europe for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC).
